Initial results from the Phase I study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors

被引：0
|
作者：
Schram, Alison [1 ]
Spreafico, Anna [2 ]
Oliva, Marc [2 ]
Brana, Irene [3 ]
Garralda, Elena [3 ]
Lakhani, Nehal [4 ]
Von Hoff, Daniel [5 ]
Borazanci, Erkut [5 ]
Pandya, Naimish [6 ]
Hoffman, Kimberly [6 ]
Hallett, Robin [6 ]
Giblin, Patricia [6 ]
Anido, Judit [6 ]
Kelly, Adrianne [6 ]
Wasserman, Robert [6 ]
Seoane, Joan [3 ]
Siu, Lillian [2 ]
Hyman, David M. [1 ]
Tabernero, Josep [3 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada
[3] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[4] START Midwest, Grand Rapids, MI USA
[5] Honor Hlth, Scottsdale, AZ USA
[6] Northern Biol, Toronto, ON, Canada
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-CT014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT014
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase 1 study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors.
    Hyman, David Michael
    Brana, Irene
    Spreafico, Anna
    Schram, Alison M.
    Pandya, Naimish B.
    Hoffman, Kimberly
    Hallet, Robin
    Giblin, Patricia
    Anido, Judit
    Ruano, Isabel Huber
    Wasserman, Robert
    Magram, Jeanne
    Siu, Lillian L.
    Tabernero, Josep
    Seoane, Joan
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Phase I dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumours: Updated results
    Borazanci, E.
    Schram, A.
    Brana, I.
    Vieito Villar, M.
    Garralda, E.
    Spreafico, A.
    Oliva, M.
    Lakhani, N.
    Wasserman, R.
    Hoffman, K.
    Hallett, R.
    Anido, J.
    Giblin, P.
    Pandya, N.
    Kelly, A.
    Seoane, J.
    Von Hoff, D. D.
    Siu, L. L.
    Hyman, D. M.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] LIF as a novel cancer immunotherapy target: modulating the tumor microenvironment with MSC-1, a humanized anti-LIF monoclonal antibody
    Magram, Jeanne
    Pandya, Naimish
    Hoffman, Kimberly
    Hallett, Robin
    Giblin, Patricia
    Sinclair, Angus
    Anido, Judit
    Ruano, Isabel Huber
    Sala, Ada
    Pascual, Monica
    Chigancas, Vanessa
    Wasserman, Robert
    Seoane, Joan
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [4] Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors
    Borazanci, E.
    Schram, A. M.
    Garralda, E.
    Brana, I
    Villar, M. Vieito
    Spreafico, A.
    Oliva, M.
    Lakhani, N. J.
    Hoffman, K.
    Hallett, R. M.
    Maetzel, D.
    Hua, F.
    Hilbert, J.
    Giblin, P.
    Anido, J.
    Kelly, A.
    Vickers, P. J.
    Wasserman, R.
    Seoane, J.
    Siu, L. L.
    Hyman, D. M.
    Hoff, D., V
    Tabernero, J.
    ESMO OPEN, 2022, 7 (04)
  • [5] A phase 1 study of serplulimab, a novel humanized monoclonal anti-PD-1 antibody, in patients with advanced solid tumors.
    Ho, Ching-Liang
    Chao, Tsu-Yi
    Chang, Chia Lun
    Lin, Hsuan-Yu
    Yang, Futang
    Wang, Qingyu
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors
    Sasaki, Yasutsuna
    Miwa, Keisuke
    Yamashita, Keishi
    Sunakawa, Yu
    Shimada, Ken
    Ishida, Hiroo
    Hasegawa, Kosei
    Fujiwara, Keiichi
    Kodaira, Makoto
    Fujiwara, Yasuhiro
    Namiki, Masayuki
    Matsuda, Minami
    Takeuchi, Yutaka
    Katsumata, Noriyuki
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (02) : 332 - 340
  • [7] A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors
    Yasutsuna Sasaki
    Keisuke Miwa
    Keishi Yamashita
    Yu Sunakawa
    Ken Shimada
    Hiroo Ishida
    Kosei Hasegawa
    Keiichi Fujiwara
    Makoto Kodaira
    Yasuhiro Fujiwara
    Masayuki Namiki
    Minami Matsuda
    Yutaka Takeuchi
    Noriyuki Katsumata
    Investigational New Drugs, 2015, 33 : 332 - 340
  • [8] A phase 1 study of ABT-806, a humanized recombinant anti-EGFR monoclonal antibody, in patients with advanced solid tumors
    Cleary, James M.
    Yee, Lorrin Kwock-Chong
    Azad, Nilofer
    Carducci, Michael
    Cosgrove, David
    Limaye, Sewanti
    Gandhi, Leena
    Pedersen, Michelle
    Ansell, Peter
    Ames, William
    Sharma, Shringi
    Hsu, Ya-Hui
    Munasinghe, Wijith
    Reilly, Edward
    Holen, Kyle D.
    Humerickhouse, Rod
    CANCER RESEARCH, 2012, 72
  • [9] A phase I, first in human study of CBA-1205, glycoengineered humanized anti-DLK-1 monoclonal antibody in patients with advanced solid tumors
    Ikeda, Masafumi
    Matsubara, Nobuaki
    Kondoh, Chihiro
    Taoka, Shose
    Katsuya, Yuki
    Koyama, Takafumi
    Yamamoto, Noboru
    CANCER RESEARCH, 2023, 83 (08)
  • [10] Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors
    Patnaik, Amita
    Kang, Soonmo Peter
    Tolcher, Anthony W.
    Rasco, Drew Warren
    Papadopoulos, Kyriakos P.
    Beeram, Muralidhar
    Drengler, Ronald
    Chen, Cong
    Smith, Lon
    Perez, Crystal
    Gergich, Kevin
    Lehnert, Manfred
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345